Arena Pharmaceuticals, Inc. (ARNA) Expected to Announce Earnings of -$0.69 Per Share
18 Août, 2017, 05:30 | Author: Claudine Rigal
American International Group Inc. increased its position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 7.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. Arena Pharmaceuticals's revenue for the quarter was down 31.8% compared to the same quarter a year ago.
Several other hedge funds have also added to or reduced their stakes in the company. AXA boosted its position in shares of Arena Pharmaceuticals by 1,420.6% in the first quarter. Wells Fargo & Company MN now owns 177,515 shares of the biopharmaceutical company's stock valued at $259,000 after buying an additional 1,050 shares during the period. TIAA CREF Investment Management LLC's holdings in Arena Pharmaceuticals were worth $1,141,000 at the end of the most recent reporting period. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Arena Pharmaceuticals by 292.6% in the first quarter. Renaissance Technologies LLC now owns 8,479,445 shares of the biopharmaceutical company's stock valued at $12,380,000 after buying an additional 957,190 shares during the period. Finally, Nationwide Fund Advisors boosted its stake in shares of Arena Pharmaceuticals by 4.8% in the first quarter. AXA now owns 568,700 shares of the biopharmaceutical company's stock valued at $830,000 after buying an additional 531,300 shares during the last quarter. Bank of America Corp DE now owns 96,379 shares of the biopharmaceutical company's stock valued at $141,000 after buying an additional 48,667 shares during the period.
Bridgepoint Education Inc (BPI) shares are moving today on volatility -3.67% or $-0.33 from the open. (NASDAQ:ARNA) fell -0.44% in morning trade Thursday. NY now owns 172,165 shares of the biopharmaceutical company's stock worth $251,000 after buying an additional 17,565 shares in the last quarter.
03/15/2017 - Arena Pharmaceuticals, Inc. had its "outperform" rating reiterated by analysts at FBR Capital Markets. In terms of moving averages, the 200-day is now at 15.68, the 50-day is 19.54, and the 7-day is resting at 21.38.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has been trading in a bullish manner, based on the relative positions of the stock's 20 and 200 day moving averages.
No more war, urges South Korea president
President Donald Trump to direct U.S. trade representative Robert Lighthizer to examine China's intellectual property practices. Tensions had escalated rapidly after land mines maimed two South Korean soldiers along the Demilitarized Zone.
As of the last earnings report the EPS was $-0.74 and is estimated to be $-2.94 for the current year with 39,220,000 shares outstanding. During the same period in the previous year, the firm posted ($1.10) EPS. The business had revenue of $6.49 million for the quarter, compared to the consensus estimate of $5.58 million. After a recent check, Arena Pharmaceuticals, Inc.'s 14-day RSI is presently at 44.828.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of global copyright & trademark legislation.
Currently, the 14-day ADX for Arena Pharmaceuticals Inc (ARNA) is sitting at 26.69.
Several equities analysts have recently weighed in on the stock. Finally, Citigroup Inc. upped their target price on Arena Pharmaceuticals from $23.00 to $37.00 and gave the company a "buy" rating in a report on Tuesday, July 11th. The stock now has a consensus rating of "Buy" and an average target price of $36.00. They issued a "buy" rating and a $23.00 price objective for the company. The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 2.10, which implies that analysts are generally neutral in their outlook for ARNA over the next year. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $37.00 target price on shares of Arena Pharmaceuticals in a research note on Monday, July 17th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. It is meant to chart the current and historical strength or weakness of a stock or market based on the closing prices of a recent trading period.
Arena Pharmaceuticals, Inc., launched on April 14, 1997, is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
Moran said about another nine sailors would face administrative punishments, and he left open the possibility of further action. Jolted awake by the crash, sailors rushed to check on their shipmates, taking actions that investigating officer Rear Adm.
The GE CEO cited Trump's remarks on Tuesday about the deadly violence in Charlottesville as his reason for leaving the committee. In the morning, Trump tweeted that Frazier's response would give him "more time to lower ripoff drug prices".
The family was rounded up by IS jihadists in their town of Sinjar in northern Iraq and held captive for two years. When he was released by ISIS this year, a relative recognized the boy in a photo posted to social media.
It has been a busy morning and we are pleased to see our students achieving their expected places at a wide range of Universities. Ross' delight was shared by his mother Jennie, who said: "I was certain he would do well, but I was still very anxious".
He declared in a statement on Twitter that there was "no room for hatred, racism or bigotry" at his company. Kevin Plank , the chief executive of Under Armour Inc .'s issued a more vague statement about his decision.
It offers a spectrum of network-based managed care plans to large and small employer, individual, Medicaid and Medicare markets. Focused Wealth Management Inc acquired a new position in shares of Anthem during the first quarter worth about $149,000.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link . Ameritas Investment Partners, Inc. expanded its holdings by buying 991 shares an increase of 54.8% in the quarter.
The governor said he is more concerned with ensuring that decisions over the North Korea's threats are executed very carefully. This, of course, all comes following North Korea being handed new sanctions by the United Nations on Saturday.
Comerica Bancorp has invested 0% in Compania Cervecerias Unidas S.A. (ADR) (NYSE:CCU). 20,992 are held by Kbc Gru Nv. The Firm operates as a brewer, soft drinks producer, water and nectar producer, wine producer and pisco distributor.
TheStreet upgraded Cliffs Natural Resources from a "d+" rating to a "c" rating in a research report on Monday, July 31st. The average revenue per share growth rate of Cliffs Natural Resources Inc. during the past 12 months was -16.6 percent.
HBO diffuse par erreur l'épisode 6 de Game of Thrones
Cet épisode S07E06 de Game of Thrones aurait du être diffusé dimanche prochain aux USA en exclusivité sur la chaîne HBO . OurMine est connu pour avoir pris le contrôle de nombreux comptes Twitter d'entreprises de divertissement américaines.